Share ownership Amgen Inc.

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-09 pm EDT			5-day change	1st Jan Change
376.97 ^USD	+2.01%		-2.26%	+15.17%

Mar. 09	Global drugmakers rush to boost US presence as tariff threat looms	RE
Mar. 05	Arcutis Biotherapeutics, Inc. Announces Promotion of Mas Matsuda to Executive Vice President, Chief Legal Officer, and Corporate Secretary	CI

Share class: Amgen Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	537,000,000	536,198,942 ( 99.85 %)	0	99.85 %

Major shareholders: Amgen Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 10.18 %	54,838,826	10.18 %	18 748 M $
BlackRock Advisors LLC 6.519 %	35,102,338	6.519 %	12 001 M $
STATE STREET CORPORATION 5.681 %	30,591,403	5.681 %	10 459 M $
Capital Research & Management Co. (World Investors) 4.289 %	23,097,711	4.289 %	7 897 M $
Capital Research & Management Co. (International Investors) 3.377 %	18,186,270	3.377 %	6 218 M $
Eaton Vance Management 2.924 %	15,744,527	2.924 %	5 383 M $
Geode Capital Management LLC 2.656 %	14,303,294	2.656 %	4 890 M $
Charles Schwab Investment Management, Inc. 2.193 %	11,811,045	2.193 %	4 038 M $
Ishares (DE) InvAG mit Teilgesellschaftsvermogen 2.053 %	11,054,197	2.053 %	3 779 M $
PRIMECAP Management Co. 1.654 %	8,904,979	1.654 %	3 044 M $
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Safra Asset CTVM SA (Investment Management) 0.000215 %	32,500	0.000215 %	397 718 $

Breakdown by shareholder type

Institutional	65.63%
Other	8.25%
State Street Corp.	5.68%
Sumitomo Mitsui Trust Group, Inc.	0.3%
Schweizerische Nationalbank	0.27%
Manulife Financial Corp.	0.22%
Individuals	0.17%
Governments	0.13%
SEI Investments Co.	0.11%
Swedbank AB	0.08%
The Bank of Nova Scotia	0.07%
Danske Bank A/S	0.05%
Fifth Third Bancorp	0.05%
First Financial Bankshares, Inc.	0.04%
Skandinaviska Enskilda Banken AB	0.03%
Banco Bilbao Vizcaya Argentaria SA	0.03%
Hancock Whitney Corp.	0.03%
Commerzbank AG	0.03%
Silvercrest Asset Management Group, Inc.	0.02%
Peapack-Gladstone Financial Corp.	0.02%
Cullen/Frost Bankers, Inc.	0.01%
First Horizon Corp. (Tennessee)	0.01%
Tompkins Financial Corp.	0.01%
The Allstate Corp.	0.01%
Kinsale Capital Group, Inc.	0.01%
AlTi Global, Inc.	0.01%
Ledyard Financial Group, Inc.	0.01%
Sumitomo Mitsui Financial Group, Inc.	0.01%
Unknown	18.71%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	63.77%
United Kingdom	4.76%
Germany	2.36%
Canada	2.32%
Norway	1.38%
France	0.98%
Japan	0.95%
Australia	0.73%
Switzerland	0.68%
Sweden	0.67%
Denmark	0.65%
South Korea	0.28%
Hong Kong	0.27%
Netherlands	0.26%
Luxembourg	0.19%
Individuals	0.17%
Belgium	0.17%
Ireland	0.16%
Italy	0.12%
China	0.11%
Finland	0.07%
Austria	0.06%
Spain	0.05%
Czech Republic	0.03%
New Zealand	0.03%
Cayman Islands	0.02%
South Africa	0.01%
Poland	0.01%
Singapore	0.01%
Brazil	0.01%
India	0.01%

Based on 1000 largest holdings

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.

Employees

31,500

Sector

Pharmaceuticals

Calendar

May. 15 - Ex-dividend date - 2.52 USD

More about the company